tiprankstipranks
Trending News
More News >
Ocumension Therapeutics (HK:1477)
:1477
Hong Kong Market

Ocumension Therapeutics (1477) AI Stock Analysis

Compare
1 Followers

Top Page

HK

Ocumension Therapeutics

(1477)

Rating:55Neutral
Price Target:
HK$9.50
▲(3.83%Upside)
Ocumension Therapeutics' score is primarily driven by strong revenue growth and a solid balance sheet, but is weighed down by profitability challenges and cash flow constraints. Technical indicators show positive momentum, yet valuation concerns persist due to negative earnings.

Ocumension Therapeutics (1477) vs. iShares MSCI Hong Kong ETF (EWH)

Ocumension Therapeutics Business Overview & Revenue Model

Company DescriptionOcumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
How the Company Makes MoneyOcumension Therapeutics generates revenue primarily through the sale of its ophthalmic products and therapies. The company's revenue model is centered around the commercialization of its proprietary and licensed products, which are marketed within China and internationally. Key revenue streams include direct sales to healthcare providers, distribution partnerships, and collaborations with other pharmaceutical companies for co-development and co-marketing opportunities. Additionally, Ocumension may engage in licensing agreements, allowing other companies to market its products in different regions, which can provide significant royalty income. The company's earnings are also influenced by its research and development activities, which may lead to new product launches, further enhancing its revenue potential.

Ocumension Therapeutics Financial Statement Overview

Summary
Ocumension Therapeutics exhibits strong revenue growth with a 69.4% increase, but its profitability is hindered by negative EBIT and net income. While the balance sheet is strong with low leverage and high equity, cash flow concerns are notable with zero operating and free cash flow.
Income Statement
45
Neutral
Ocumension Therapeutics showcases strong revenue growth, with a notable increase in total revenue from the previous year (+69.4%). However, the company continues to operate at a loss with negative EBIT and net income, impacting its net profit margin (-64.3%) and EBIT margin (-73.4%). Gross profit margin remains healthy at 53.9%, indicating operational efficiency in production.
Balance Sheet
60
Neutral
The company's balance sheet is strong with high equity levels, as evidenced by a low debt-to-equity ratio (0.01) and a high equity ratio (94.96%). However, the return on equity is negative (-7.11%) due to sustained net losses. The low leverage and high cash reserves suggest financial stability, but profitability remains a concern.
Cash Flow
35
Negative
The cash flow position is challenging, with zero operating cash flow and free cash flow, indicating potential liquidity issues. The absence of cash flow from operations despite revenue growth highlights operational cash constraints. Previous periods show negative free cash flow, suggesting ongoing cash management challenges.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue417.31M246.37M158.96M56.15M13.10M
Gross Profit225.06M144.37M102.92M36.94M11.37M
EBITDA-260.05M-320.62M-359.98M-371.30M-2.26B
Net Income-268.27M-379.79M-402.64M-134.78M-2.26B
Balance Sheet
Total Assets3.97B3.27B3.04B3.33B2.60B
Cash, Cash Equivalents and Short-Term Investments769.21M1.05B1.29B1.77B2.03B
Total Debt25.78M137.98M29.58M11.21M7.24M
Total Liabilities200.19M351.03M295.04M222.88M97.23M
Stockholders Equity3.77B2.92B2.75B3.11B2.50B
Cash Flow
Free Cash Flow-408.97M-539.79M-510.66M-861.66M-517.18M
Operating Cash Flow-178.83M-177.93M-200.66M-196.85M-212.57M
Investing Cash Flow275.91M-259.78M229.15M-1.35B629.70M
Financing Cash Flow-213.79M108.66M-9.22M668.85M1.53B

Ocumension Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price9.15
Price Trends
50DMA
7.81
Positive
100DMA
6.27
Positive
200DMA
5.65
Positive
Market Momentum
MACD
0.47
Positive
RSI
48.77
Neutral
STOCH
11.41
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1477, the sentiment is Neutral. The current price of 9.15 is below the 20-day moving average (MA) of 10.04, above the 50-day MA of 7.81, and above the 200-day MA of 5.65, indicating a neutral trend. The MACD of 0.47 indicates Positive momentum. The RSI at 48.77 is Neutral, neither overbought nor oversold. The STOCH value of 11.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1477.

Ocumension Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
HK$8.07B-3.29%3.76%-833.33%
55
Neutral
HK$7.51B-8.04%66.72%33.68%
55
Neutral
HK$6.94B-22.23%-14.17%76.00%
52
Neutral
$7.45B0.27-61.87%2.30%16.62%1.04%
51
Neutral
HK$8.90B-51.40%58.75%-1310.16%
48
Neutral
HK$1.34B-12.04%260.78%40.04%
HK$7.04B82.074.95%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1477
Ocumension Therapeutics
8.90
2.10
30.88%
HK:2157
Lepu Biopharma Co. Ltd. Class H
5.22
2.05
64.67%
HK:2616
CStone Pharmaceuticals
5.18
3.95
321.14%
HK:6622
Zhaoke Ophthalmology Ltd.
2.48
1.09
78.42%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
12.68
3.67
40.73%
HK:0775
CK Life Sciences International (Holdings), Inc.
0.87
0.53
155.88%

Ocumension Therapeutics Corporate Events

Ocumension Therapeutics Updates Nomination Committee
Jun 30, 2025

Ocumension Therapeutics has announced changes to its Nomination Committee in response to upcoming amendments to the Corporate Governance Code. Dr. Qin XIE and Mr. Ting Yuk Anthony WU have been appointed as new members, effective June 30, 2025, enhancing the committee’s composition with a blend of independent and non-executive directors.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Announces Board Composition and Roles
Jun 30, 2025

Ocumension Therapeutics has announced the composition of its board of directors and the roles of each member, highlighting the leadership structure and committee memberships. This announcement provides clarity on the governance of the company, which is crucial for stakeholders to understand the decision-making framework and oversight within the organization.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Updates Nomination Committee Terms
Jun 30, 2025

Ocumension Therapeutics has updated the terms of reference for its Nomination Committee, which is responsible for identifying and recommending candidates for the company’s board of directors. This move is part of the company’s efforts to ensure compliance with applicable laws and listing standards, and to enhance the governance process by including a diverse and independent board composition.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Revamps Share Option Scheme to Boost Employee Incentives
Jun 24, 2025

Ocumension Therapeutics announced the cancellation and re-granting of options as part of its 2021 Share Option Scheme. The company canceled 4,018,842 options and re-granted 2,813,189 replacement options to 155 existing grantees, representing approximately 0.35% of the total shares. Additionally, Ocumension granted 15,462,865 new options and 8,952,185 awards to 430 grantees as further incentives, representing 1.90% and 1.10% of the total shares, respectively. This move aims to provide meaningful incentives and retain key personnel by aligning the exercise price with the prevailing market price of shares.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Successfully Passes All AGM Resolutions
Jun 19, 2025

Ocumension Therapeutics announced that all resolutions proposed at their Annual General Meeting on June 19, 2025, were passed as ordinary resolutions. Key resolutions included the re-election of directors, the re-appointment of auditors, and the authorization for the board to manage shares, reflecting strong shareholder support and potentially enhancing the company’s governance and operational capabilities.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Gains Approval for Phase III Trial of Presbyopia Treatment in China
Jun 10, 2025

Ocumension Therapeutics has received authorization to initiate a phase III clinical trial for OT-802, a self-developed treatment for presbyopia, in China. This development underscores the company’s research capabilities and highlights the significant commercial potential in the underserved presbyopia treatment market in the region.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension’s OT-703 Approved for Study in Hainan
May 13, 2025

Ocumension Therapeutics announced that its product OT-703, an injectable fluocinolone intravitreal implant for diabetic macular edema, has been approved for a real-world study in Hainan, China. This approval marks a significant step in the company’s efforts to expand its presence in the Asian market, following its exclusive licensing agreement with Alimera Sciences for the development and commercialization of ILUVIEN in Greater China and other regions.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Announces 2025 Annual General Meeting
Apr 28, 2025

Ocumension Therapeutics has announced its upcoming annual general meeting scheduled for June 19, 2025, in Shanghai. The meeting will address several key resolutions, including the adoption of the company’s financial statements for 2024, the re-election of directors, and the reappointment of Deloitte Touche Tohmatsu as auditors. Additionally, the meeting will consider authorizing the board to issue additional shares, which could impact the company’s capital structure and market operations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025